SYDNEY, AUSTRALIA: BPH Global, a company that specializes in birds’ nest products and stem cell technologies, has announced that it will acquire 100% of Foshan Gedishi Biotechnology Co, a company that operates a birds’ nest pilot study with BPH Global’s China partners.

The acquisition is considered a major milestone in the revitalization of BPH Global’s birds’ nest business in China.

Foshan Gedishi Biotechnology Co is a company that sells and distributes birds’ nest products in China, mainly through its online platform on Douyin, a popular social media app. Foshan is one of the few accredited sellers of birds’ nest products on Douyin, which requires sellers to demonstrate the authenticity of their products. Foshan also has a strong relationship with China Tobacco, a state-owned enterprise that is the largest tobacco company in the world.

By acquiring Foshan, BPH Global will gain full control of the operation and direction of the business and be able to consolidate its financials. BPH Global will also leverage Foshan’s platform and brand recognition to extend its birds’ nest sales and distribution operations into other areas of China. Moreover, BPH Global will be in an enhanced position to negotiate birds’ nest supply agreements with suppliers from Malaysia and Indonesia.

BPH Global also plans to use Foshan’s sale and distribution channels to provide opportunities for its other potential supply arrangements, including its own stem cell technologies and its joint venture with Singapore-based Chemokine Yuesheng Pte Ltd, which focuses on infusing nutraceuticals extracted from birds’ nests into food products for sale in the Chinese market.